Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action

International Journal of Risk and Safety in Medicine

Volumn 12, Issue 1, 1999, Pages 3-35

  Breggin, Peter R ^a,b  

^a International Center for the Study of Psychiatry and Psychology (ICSPP)   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; FLUOXETINE; GRADUMET; METHAMPHETAMINE; METHYLPHENIDATE; PAROXETINE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG;

AGITATION; ALERTNESS; APATHY; ATTENTION DEFICIT DISORDER; CARDIOTOXICITY; CHILD; COMPULSION; DEPRESSION; DRUG DEPENDENCE; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HYPOMANIA; INSOMNIA; NEUROTOXICITY; PSYCHOSOCIAL WITHDRAWAL; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE;

EID: 0033012552     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (177)

1. Aarskog, D., Fevang, F., Klove, H., Stoa, K., & Thorsen, T. (1977). The effect of stimulant drugs, dextroamphetamine and methylphenidate, on secretion of growth hormone in hyperactive children. Journal of Pediatrics, 90, 136-139.
2. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (Fourth Edition). Washington, DC: APA.
3. Arakawa, O. (1994). Effects of methamphetamine and methylphenidate on single and paired rat open-field behaviors. Physiology & Behavior, 55, 441-446.
4. Armstrong, T. (1995). The myth of the A.D.D. child. New York: Dutton.
5. Arnold, L.E., & Jensen, P.S. (1995). Attention-deficit disorders. In H.I. Kaplan & Sadock, B. (Eds.). Comprehensive textbook of psychiatry (Fourth Edition), pp. 2295-2310. Baltimore, MD: Williams & Wilkins.
6. Baldwin, K., Brown, R.T., & Milan, M.A. (1995). Predictors of stress in caregivers of attention deficit hyperactivity disordered children. American Journal of Family Therapy, 23, 149-160.
7. Barbarin, O., & Soler, R.E. (1993). Behavioral, emotional, and academic adjustment in a national probability sample of African American children: Effects of age, gender, and family structure. Journal of Black Psychology, 19, 423-446.
8. Barkley, R.A., & Cunningham, C.E. (1979). The effects of methylphenidate on the mother-child interactions of hyperactive children. Archives of General Psychiatry, 36, 201-208.
9. Barkley, R.A., Karlsson, J., Pollard, S., & Murphy, J.V. (1985). Developmental changes in the mother-child interactions of hyperactive boys: Effects of two dose levels of Ritalin. Journal of Child Psychology, 26, 705-715.
10. Barkley, R.A., McMurray, M.B., Edelbrock, C.S., & Robbins, K. (1990). Side effects of methylphenidate in children with attention deficit disorder: A systemic, placebo-controlled evaluation. Pediatrics, 86, 184-192.
11. Barnett, J.V., & Kuczenski, R. (1986). Desensitization of rat striatal dopamine-stimulated adenylate cyclase after acute amphetamine administration. Journal of Pharmacology and Experimental Therapeutics, 237, 820-825.
12. Barter, M., & Kammer, H. (1978). Methylphenidate and growth retardation. Journal of the American Medical Association, 239, 1742-1743.
13. Battaglia, G., Yeh, S.Y., O'Hearn, E., Molliver, M.E., Kuhar, M.J. & De Souza, E.B. (1987). 3,4-methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain. Journal of Pharmacology and Experimental Therapeutics, 242, 911-916.
14. Bauer, B. (1989). Kids talk about the 'good pill'. Science News, 135, p. 332.
15. Bell, R.D., Alexander, G.M., Schwartzman, R.J., & Yu, J. (1982). The methylphenidate-induced stereotypy in the awake rat: Local cerebral metabolism. Neurology, 32, 377-381.
16. Bhattacharyya, A.K., Ghosh, B., Aulakh, C.S., & Pradhan, S.N. (1980). Correlation of behavioral and neurochemical effects of acute administration of methylphenidate in rats. Progress in Neuro-Psychopharmacology, 4, 129-136.
17. Borcherding, B.V., Keysor, C.S., Rapoport, J.L., Elia, J., & Amass, J. (1990). Motor/vocal tics and compulsive behaviors on stimulant drugs: Is there a common vulnerability. Psychiatric Research, 33, 83-94.
18. Breggin, P.R. (1964). The psychophysiology of anxiety. Journal of Nervous Mental Disease, 139, 558-568.
19. Breggin, P.R. (1965). The sedative-like effect of epinephrine. Archives of General Psychiatry, 12, 255-259.
20. Breggin, P.R. (1990). Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptic drugs: Evidence, etiology, implications. Journal of Mind and Behavior, 11, 425-464.
21. Breggin, P.R. (1993). Parallels between neuroleptic effects and lethargic encephalitis: The production of dyskinesias and cognitive disorders. Brain and Cognition, 23, 8-27.
22. Breggin, P.R. (1997). Brain-disabling treatments in psychiatry. New York: Springer Publishing Company.
23. Breggin, P.R. (1998a). Talking back to Ritalin. Monroe, ME: Common Courage Press.
24. Breggin, P.R. (1998b). Data compiled and analyzed by the author from Food and Drug Administration (1997).
25. Breggin, P.R. (1998c). Analysis of adverse behavioral effects of benzodiazepines with a discussion of drawing scientific conclusions from the FDA's Spontaneous Reporting System. Journal of Mind and Behavior, 19, 21-50.
26. Breggin, P.R. (1998d). Risks and mechanism of action of stimulants. NIH consensus development conference program and abstracts: Diagnosis and treatment of attention deficit hyperactivity disorder, pp. 105-120. Rockville, Maryland: National Institutes of Health.
27. Breggin, P.R. & Breggin, G. (1994). Talking back to Prozac. New York: St. Martin's.
28. Breggin, P.R. & Breggin, G. (1996). The hazards of treating 'Attention-Deficit/Hyperactivity Disorder' with methylphenidate (Ritalin) Journal of College Student Psychotherapy 10:55-72.
29. Breggin, P.R. & Breggin, G. (1998). The war against children of color. Monroe, ME: Common Courage Press.
30. Brown, R.T. & Sexson, S.B. (1988). A controlled trial of methylphenidate in black adolescents. Clinical Pediatrics, 27, 74-81.
31. Brown, W.A. & Williams, B.W. (1976). Methylphenidate increases serum growth hormone concentrations. Journal of Clinical Endocrinology and Metabolism, 43, 937-938.
32. Buhrmester, D., Whalen, C., Henker, B., MacDonald, V., & Hinshaw, S.P. (1992). Prosocial behavior in hyperactive boys: Effects of stimulant medication and comparison with normal boys. Journal of Abnormal Child Psychology, 20, 103-121.
33. Camp, D.M., DeJonghe, D.K., & Robinson, T.E. (1997). Time-dependent effects of repeated amphetamine treatment on norepinephrine in the hypothalamus and hippocampus assessed with in vivo microdialysis. Neuropsychopharmacology, 17, 130-140.
34. Carey, W.B. (1998). Is attention deficit hyperactivity a valid disorder? NIH consensus development conference program and abstracts: Diagnosis and treatment of attention deficit hyperactivity disorder, pp. 33-6. Rockville, MD: National Institutes of Health.
35. Castellanos, F.X., Giedd, J.N., Elia, J., Marsh, W.L., Ritchie, G.F., Hamburger, S.D., & Rapoport, J.L. (1997). Controlled stimulant treatment of ADHD and Comorbid Tourette's syndrome: Effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 589-596.
36. Castellanos, F.X., Giedd, J.N., Marsh, W.L., Hamburger, S.D., Vaituzis, A.C., Dickstein, D.P., Sarfatti, S.E., Vauss, Y.C., Snell, J.W., Lange, N., Kaysen, D., Krain, A.L., Ritchie, G.F., Rajapakse, J.C., & Rapoport, J.L. (1998). Quantitative brain magnetic resoance imaging in attention-deficit hyperactivity disorder. Archives of General Psychiatry, 53, 607-616.
37. Chugani, H.T., Phelps, M.E., & Mazziotta, J.C. (1987). Positron emission tomography study of human brain functional development. Annals of Neurology, 22, 487-497.
38. Conti, L.H., Segal, D.S., & Kuczenski, R. (1997). Maintenance of amphetamine-induced stereotypy and locomotion requires ongoing dopamine receptor activation. Psychopharmacology, 130, 183-188.
39. Costall, B. & Naylor, R.J. (1974). The involvement of dopaminergic systems with the stereotyped behavior patterns induced by methylphenidate. Journal of Pharmacy and Pharmacology, 26, 30-33.
40. Cotton, M.F. & Rothberg, A.D. (1988). Methylphenidate v. placebo: A randomized double-blind crossover study in children with attention deficit disorder. South African Medical Journal, 74, 268-271.
41. Cunningham, C.E. & Barkley, R.A. (1978). The effects of methylphenidate on the mother-child interactions of hyperactive identical twins. Developmental Medicine And Child Neurology, 20, 634-642.
42. Drug Enforcement Administration (DEA). (1995, October). Methylphenidate (A background paper). Washington, DC: Drug and Chemical Evaluation Section, Office of Diversion Control, DEA, US Department of Justice.
43. Drug Enforcement Administration (DEA). (1996). Conference report: Stimulant use in treatment of ADHD. Washington, DC: Drug and Chemical Evaluation Section, Office of Diversion Control, DEA, US Department of Justice.
44. Dulcan, M. (1994). Treatment of Children and Adolescents. In R. Hales, Yudofsky, S. & Talbott, J. (Eds.), The American Psychiatric Press textbook of psychiatry (Second Edition), pp. 1209-1250. Washington, DC: American Psychiatric Press.
45. Dulcan, M. & Popper, C. (1991). Concise guide to child and adolescent psychiatry. Washington, DC: American Psychiatric Press.
46. Dunnick, J.K. & Hailey, J.R. (1995). Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology, 103, 77-84.
47. Dyme, I.Z., Sahakian, B.J., Golinko, B.E., & Rabe, E.F. (1982). Perseveration induced by methylphenidate in children: Preliminary findings. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 6, 269-273.
48. Efron, D., Jarman, F.C., & Barker, M.J. (1998). Child and parent percreptions of stimulant medication treatment in attention deficit hyperactivity disorder. Journal of Paediatric and Child Health, 34, 288-292.
49. Ellinwood, E.H. & Cohen, S. (1972). Current concepts of amphetamine abuse. Rockville, MD: National Institute of Mental Health. DHEW Publication No. (HSM) 72-9085.
50. Ellinwood, E.H. & Tong, H.L. (1996). Central nervous system stimulants and anorectic agents. In M.N.G. Dukes (Ed.). Meyler's side effects of drugs: An encyclopedia of adverse reactions and interactions (Thirteen Edition), pp. 1-30. New York: Elsevier.
51. Emslie, G.J., Rush, A.J., Weinberg, W.A., Kowatch, R.A., Hughes, C.W., Carmody, T., & Rintelmann, J. (1997). A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry, 54, 1031-1037.
52. Ernst, M., Zametkin, A.J., Matochik, J., Schmidt, M., Jons, P.H., Liebenauer, L.L., Hardy, K.K., & Cohen, R.M. (1997). Intravenous dextroamphetamine and brain glucose metabolism. Neuropsychopharmacology, 17, 391-401.
53. Feussner, G. (1998). Diversion, trafficking, and abuse of methylphenidate. NIH consensus development conference program and abstracts: Diagnosis and treatment of attention deficit hyperactivity disorder, pp. 201-4. Rockville, MD: National Institutes of Health.
54. Fialkov, J.M. & Hasley, S. (1984). Psychotropic drug effects contributing to psychiatric hospitalization of children: A preliminary study. Developmental and Behavioral Pediatrics, 5, 325-330.
55. Firestone, P., Musten, L. M., Pisterman, S., Mercer, J., & Bennett, S. (1998). Short-term side effects of stimulant medications in preschool children with attention-deficit/hyperactivity disorder: A double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology, 8, 13-25.
56. Flaum, M. & Schultz, S.K. (1996). When does amphetamine-induced psychosis become schizophrenia? American Journal of Psychiatry, 153, 812-815.
57. Food and Drug Administration. (1996, October). The clinical impact of adverse event reporting. A MedWatch continuing education article. Rockville, MD: Staff College, Center for Drug Evaluation and Research, author.
58. Food and Drug Administration. (1997, March). Spontaneous Reporting System (SRS) data for methylphenidate: 1985 through March 3, 1997. Rockville, MD. Obtained through the Freedom of Information Act.
59. Fuller, R.W., Perry, K.W., & Molloy, B.B. (1974). Effect of an uptake inhibitor on serotonin metabolism in rat brain. Life Sciences, 15, 1161-1171.
60. Giedd, J.N., Castellanos, F.X., Casey, B.J., Kozuch, P., King, A. C., Hamburger, S.D., & Rapoport, J.L. (1994). Quantitative morphology of the corpus callosum in attention deficit hyperactivity disorder. American Journal of Psychiatry, 151, 665-669.
61. Gillberg, C., Melander, H., von Knorring, A-L., Janols, L-O., Thernlund, G., Hagglof, B., Eidevall-Wallin, L., Gustafsson, P., & Kopp S. (1997). Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: A randomized, double-blind, placebo-controlled trial. Archives of General Psychiatry 54, 857-864.
62. Gittelman-Klein, R., Klein, D.F., Katz, S., Saraf, K., and Pollack, E. (1976). Comparative effects of methylphenidate and thioridazine in hyperkinetic children. Archives of General Psychiatry, 33, 1217-1231.
63. Granger, D.A., Whalen, C.K., & Henker, B. (1993). Perceptions of methylphenidate effects of hyperactive children's peer interactions. Journal of Abnormal Child Psychology, 21, 535-549.
64. Greenough, W.T. & Black J.E. (1992). Induction of brain structure by experience: Substrates for cognitive development. In M. Gunnar & Nelson, C. (Eds.), Developmental Behavioral Neuroscience, Volume 24: Minnesota Symposia on Child Development, pp. 155-200. Hillsdale, NJ: Lawrence Erlbaum.
65. Handen, B.L., Feldman, H., Gosling, A., Breaux, A.M., & McAuliffe, S. (1990). Adverse side effects of methylphenidate among mentally retarded children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 241-245.
66. Henderson, T.A. & Fischer, V.W. (1994). Effects of methylphenidate (Ritalin) on mammalian myocardial ultrastructure. American Journal of Cardiovascular Pathology, 5, 68-78.
67. Huang, N.-K., Wan, F.-J., Tseng, C.-J., and Tung, C.-S. (1997). Amphetamine induces hydroxyl radical formation in the striatum of rats. Life Sciences, 61, 2219-2229.
68. Hughes, R.N. (1972). Methylphenidate induced inhibition of exploratory behavior in rats. Life Sciences, 11, 161-167.
69. Huttenlocher, P.R. (1990). Morphometric study of human cerebral cortex development. Neuropsychologia, 28, 517-527.
70. Hynd, G.W., Semrud-Clikeman, M., Lorys, A.R., Novey, E.S., Eliopulos, D., & Lyytinen, H. (1991). Corpus callosum morphology in attention deficit-hyperactivity disorder: Morphometric analysis on MRI. Journal of Learning Disabilities, 24, 141-145.
71. Indiana Prevention Resource Center Survey (1998). Alcochol, tobacco, and other drug use by Indiana children and adolescents: Executive summary and highlights. [On-line]. Available: http://www.drugs.indiana.edu/drug_stats/exec98.html.
72. International Center for the Study of Psychiatry and Psychology (ICSPP). Address: 4628 Chestnut Street, Bethesda, MD 20814, USA.
73. International Narcotics Control Board. (INCB). (1995, February 28). Dramatic increase in methylphenidate consumption in US: Marketing methods questioned. INCB Annual Report 1995: Background Note No. 2 Vienna, Austria: Author.
74. International Narcotics Control Board. (INCB). (1997, March 4). INCB sees continuing risk in stimulant prescribed for children. INCB Annual Report Background Note No. 4. Vienna, Austria: Author.
75. Ishiguro, Y. & Morgan, J.P. (1997). Biphasic inotropic effects of methamphetamine and methylphenidate on ferret papillary muscles. Journal of Cardiovascular Pharmacology, 30, 744-749.
76. Jacobvitz, D., Sroufe, L.A., Stewart, M., & Leffert, N. (1990). Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: A comprehensive review. Journal of the American Academy of Child and Adolescent Psychiatry, 29, 677-688.
77. Jensen, P.S., Bain, M.W., & Josephson, A.M. (1989). Why Johnny can't sit still: Kids' ideas why they take stimulants, unpublished paper from the Division of Neuropsychiatry, Walter Reed Army Institute of Research, Washington, DC.
78. Joyce, P.R., Donald, R.A., Nicholls, M.G., Livesey, J.H., & Abbott, R.M. (1986). Endocrine and behavior responses to methylphenidate in normal subjects. Biological Psychiatry, 21, 1015-1023.
79. Juan, J., McCann, U., and Ricaurte, G. (1997). Methylphenidate and brain dopamine neurotoxicity. Brain Research, 767, 172-175.
80. Karch, S.B. (1996). The pathology of drug abuse (Second Edition). Boca Raton, FL: CRC Press.
81. Kessler, D. (1993). Introducing MedWatch: A new approach to reporting medication and device adverse effects and product problems. Journal of the American Medical Association, 269, 2765-2768.
82. King, R.A., Riddle, M.A., Chappell, P.B., Hardin, M.B.T., Anderson, G.M., Lombroso, P., & Scahill, L. (1991). Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 179-186.
83. Klein, R.G., Landa, B., Mattes, J.A., & Klein, D.F. (1988). Methylphenidate and growth in hyperactive children. Archives of General Psychiatry, 45, 1127-1130.
84. Klein, R.G. & Mannuzza, S. (1988). Hyperactive boys almost grown up: III. Methylphenidate effects on ultimate height. Archives of General Psychiatry, 45, 1131-1134.
85. Koek, W. & Colpaert, F.C. (1993). Inhibition of methylphenidate-induced behaviors in rat: Differences among neuroleptics. Journal of Pharmacology and Experimental Therapeutics, 267, 181-191.
86. Koizumi, H.M. (1985). Obsessive-compulsive symptoms following stimulants (letter). Biological Psychiatry, 20, 1332-1333.
87. Koreen, A.R., Lieberman, J.A., Alvir, J., & Chakos, M. (1997). The behavioral effect of m-chlorophenylpiperazine (MCPP) and methylphenidate in first-episode schizophrenia and normal controls. Neuropsychopharmacology, 16, 61-68.
88. Koslow, S.H. (Ed.). (1995). The neuroscience of mental health, II. Rockville, MD: National Institutes of Health and National Institute of Mental Health. NIH Publication No. 95-4000.
89. Kouris, S. (1998). Methylphenidate-induced obsessive-compulsiveness. (letter). Journal of the American Academy of Child and Adolescent Psychiatry, 37, 135.
90. Kramer, J.C., Lipton, M., Ellinwood, Jr., E.H., & Sulser, F. (chairmen). (1970). Discussion of part II. In E.H. Ellinwood & S. Cohen (Eds.), Current concepts on amphetamine abuse: Proceedings of a workshop, Duke University Medical Center, June 5-6, 1970. Rockville, MD: National Institutes of Mental Health.
91. Kuczenski, R. & Segal, D.S. (1997). Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: Comparison with amphetamine. Journal of Neurochemistry, 68, 2032-2037.
92. Lacroix, D. & Ferron, A. (1988). Electro-physiological effects of methylphenidate on the coeruleo-cortical noradrenergic system of the rat. European Journal of Pharmacology, 149, 277-285.
93. Lambert, N.M. (1998). Stimulant treatment as a risk factor for nicotine use and substance abuse. NIH consensus development conference program and abstracts: Diagnosis and treatment of attention deficit hyperactivity disorder, pp. 191-200. Rockville, MD: National Institutes of Health.
94. Lambert, N.M., & Hartsough, C.S. (in press). Prospective study of tobacco smoking and substance dependence among samples of ADHD and non-ADHD subjects. Journal of Learning Disabilities.
95. Leber, P. (1992). Postmarketing surveillance of adverse drug effects. In J. Kane and J. Lieberman (Eds.), Adverse effects of psychotropic drugs, pp. 3-12. New York: Guilford Press.
96. Lee, V.E., Brooks-Gunn, J., Schnur, E., & Fong-Ruey, L. (1990). Are Head Start effects sustained? A longitudinal follow-up comparison of disadvantaged children attending Head Start, no preschool, and other preschool programs. Child Development, 61, 495-507.
97. Lieberman, J.A., Kane, J.M., & Alvir, J. (1987). Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology, 91, 415-433.
98. Lipkin, P.H., Goldstein, I.J., & Adesman, A. R. (1994). Tics and dyskinesias associated with stimulant treatment for attention-deficit hyperactivity disorder. Archives of Pediatric and Adolescent Medicine, 148, 859-861.
99. Lou, H.C., Henriksen, L., & Bruhn, P. (1984). Focal cerebral hypoperfusion in children with dysphasia and/or attention deficit disorder. Archives of Neurology, 41, 825-829.
100. Mach, R.H., Nader, M.A., Ehrenkaufer, R.L.E., Line, S.W., Smith, C.R., Gage, H.D., & Morton, T.E. (1997). Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release. Pharmacology Biochemistry and Behavior, 57, 477-486.
101. MacKenzie, R.G., & Heischober, B. (1997). Methamphetamine. Pediatrics in Review, 18, 305-309.
102. Mannuzza, S., Klein R.G., Bessler, A., Malloy, P., & LaPadula, M. (1993). Adult outcome of hyperactive boys: Educational achievement, occupational rank, and psychiatric status. Archives of General Psychiatry, 50, 565-576.
103. Mannuzza, S., Klein, R.G., Bessler, A., Malloy, P., & LaPadula, M. (1998). Adult psychiatric status of hyperactive boys grown up. American Journal of Psychiatry, 155, 493-498.
104. Mathieu, J-F, Perron, A., Dewar, K.M., & Reader, T.A. (1989). Acute and chronic effects of methylphenidate on cortical adrenoreceptors in the rat. European Journal of Pharmacology, 162, 173-178.
105. Maxmen, J.S. & Ward, N.G. (1995). Psychotropic drugs fast facts (Second Edition). New York: W.W. Norton.
106. Mayes, S.D., Crites, D.L., Bixler, E.O, Humphrey II, F.J., & Mattison, R.E. (1994). Methylphenidate and ADHD: Influence of age, IQ and neurodevelopmental status. Developmental Medicine and Children Neurology, 36, 1099-1107.
107. Melega, W.P., Raleigh, M.J., Stout, D.B., Huang, S.C., & Phelps, M.E. (1997a). Ethological and 6-[18F]fiuoro-L-DOPA-PET profiles of long-term vulnerability to chronic amphetamine. Behavioural Brain Research, 84, 258-268.
108. Melega, W.P., Raleigh, M.J., Stout, D.B., Lacan, G., Huang, S.C., & Phelps, M.E. (1997b). Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Research, 766, 113-20.
109. McCann, U.D., Seiden, L.S., Rubin, L.J., & Ricaurte, G.A. (1997). Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: A systematic review of evidence. Journal of the American Medical Association, 278, 666-672.
110. McGuinness, D. (1989). Attention deficit disorder: The emperor's new clothes, animal "pharm", and other fiction. In Fisher, S. and Greenberg, R.P. (Eds.). The limits of biological treatments for psychological distress. Hillsdale, NJ: Lawrence Erlbaum Associates, pp. 151-188.
111. Mueller, K. (1993). Locomotor stereotypy is produced by methylphenidate and amfonelic acid and reduced by haloperidol but not clozapine or thioridazine. Pharmacology Biochemistry and Behavior, 45, 71-76.
112. Murray, J.B. (1998). Psychophysiological aspects of amphetamine-methamphetamine abuse. Journal of Psychology, 132, 227-237.
113. Nasrallah, H., Loney, J., Olson, S., McCalley-Whitters, M., Kramer, J., & Jacoby, C. (1986). Cortical atrophy in young adults with a history of hyperactivity in childhood. Psychiatry Research 17:241-246.
114. National Institutes of Health (1998, November 19). Consensus statement: Diagnosis and treatment of attention deficit hyperactivity disorder (draft). Rockville, MD: Author. Obtained from the NIH website: http://odp.od.nih.gov/consensus/cons/110/ 110_statement.
115. National Institute of Mental Health (NIMH) and the Food and Drug Administration (FDA). (1995, January 24-25). Psychopharmacology in child and adolescents: Current problems, future prospects. Conference held in Washington, DC. Obtained through the Freedom of Information Act.
116. National Toxicology Program. (1995). NTP technical report on toxicology and carcinogenesis studies of methylphenidate hydrochloride in F344/N rats and B6C3F mice (feed studies). Rockville, MD: National Institutes of Health. NIH Publication No. 95-3355.
117. Panksepp, J. (in press). A critical analysis of ADHD, psychostimulants, and intolerance of child impulsivity: A national tragedy in the making? Current Directions in Psychological Sciences.
118. Panksepp, J., Normansell, L.A., Cox, J.F., Crepeau, L., & Sacks, D.S. (1987). Psychopharmacology of social play. In J. Mos (Ed.). Ethnopharmacology of social behavior, pp. 132-144. Holland: Duphar.
119. Physicians' Desk Reference. (1998) Montvale, NJ: Medical Economics.
120. Popper, C.W., & Steingard, R.J. (1994). Disorders usually first diagnosed in infancy, childhood, or adolescence. R. Hales, Yudofsky, S. & Talbott, J. (Eds.), The American Psychiatric Press textbook of psychiatry (Second Edition). Washington, DC: American Psychiatric Press, pp. 729-832.
121. Porrino, L.J., & Lucignani, G. (1987). Different patterns of local brain energy metabolism associated with high and low doses of methylphenidate: Relevance to its action in hyperactive children. Biological Psychiatry, 22, 126-128.
122. Porrino, L., Rapoport, J., Behar, D., Ismond, D., & Bunney, W. (1983). A naturalistic assessment of the motor activity of hyperactive boys: Part II. Stimulant drug effects. Archives of General Psychiatry, 40, 688-693.
123. Randrup, A. & Munkvad, I. (1967). Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia, 11, 300-310.
124. Rapoport, J.L., Buchsbaum, M.S., Zahn, T.P., Weingartner, H., Ludlow, C., & Mikkelsen, E. (1978). Dextroamphetamine: Cognitive and behavior effects in normal prepubertal boys. Science, 199, 565-563.
125. Rapoport, J.L., Buchsbaum, M.S., Weingartner, H., Zahn, T.P., Ludlow, C., & Mikkelsen, E.J. (1980). Dextroamphetamine: Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Archives of General Psychiatry, 37, 933-943.
126. Rebec, G.V. & Bashore, T.R. (1984). Critical issues in assessing the behavioral effects of amphetamine. Neuroscience & Behavioral Reviews, 8, 153-159.
127. Rebec, G.V. & Segal, D.S. (1980). Apparent tolerance to some aspects of amphetamine stereotypy with long-term treatment. Pharmacology Biochemistry & Behavior, 13, 793-797.
128. Rebec, G.V., White, I.M., & Puotz, J.K. (1997). Responses of neurons in dorsal striatum during amphetamine-induced focused stereotypy. Psychopharmacology, 130, 343-341.
129. Regier, D.A. & Leshner, A.I. (1992, February). Request for Applications: Cooperative Agreement for a multi-site, multimodel treatment study of attention-deficit hyperactivity Disorder (ADHD)/Attention-Deficit Disorder (ADD). MH-92-03. Washington, DC: Department of Health and Human Services.
130. Richters, J.E., Arnold, L.E., Jensen, P.S., Abikoff, H., Conners, C.K., Greenhill, L.L., Hechtman, L., Hinshaw, S.P., Pelham, W.E., & Swanson, J.M. (1995). NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 987-1000.
131. Riddle, M.A., King, R.A., Hardin, M.T., Scahill, L., Ort, S.I., Chappell, P., Rasmusson, A., & Leckman J.F. (1990/1991). Behavioral side of fluoxetine in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 1, 193-198.
132. Rie, H.E., Rie, E.D., Stewart, S., & Ambuel, J.P. (1976). Effects of methylphenidate on underachieving children. Journal of Consulting and Clinical Psychology, 44, 250-260.
133. Robbins, T.W. & Sahakian, B.J. (1979). "Paradoxical" effects of psychomotor stimulant drugs in hyperactive children from the standpoint of behavioural pharmacology. Neuropharmacology, 18, 931-950.
134. Robinson, T.E. & Badiani, A. (1998). Drug-induced adaptations in catecholamine systems: On the inevitability of sensitization. Advances in Pharmacology, 42, 987-990.
135. Robinson, T.E. & Kolb, B. (1997). Persistent structural modifications in the nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. Journal of Neuroscience, 17, 8491-7.
136. Safer, D.J., Allen, R.P., & Barr, E. (1975). Growth rebound after termination of stimulation drugs. Journal of Pediatrics, 86, 113-116.
137. Sams-Dodd, F., & Newman, J.D. (1997). Effects of administration regime on the psychotomimetic properties of d-amphetamine in the squirrel monkey (Saimiri sciureus). Pharmacology Biochemistry and Behavior, 56, 471-480.
138. Scahill, L. & Lynch, K.A. (1994, October-December). Use of methylphenidate in children with attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychiatric Nursing, 7, 44-46.
139. Schachar, R.J., Tannock, R., Cunningham, C., & Corkum, P. V. (1997). Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 754-763.
140. Schiorring, E. (1979). Social isolation and other behavioral changes in groups of adult vervet monkeys (Cercopithecus aethiops) produced by low, nonchronic doses of d-amphetamine. Psychopharmacology, 64, 297-302.
141. Schiorring, E. (1981). Psychopathology induced by "speed drugs". Pharmacology Biochemistry & Behavior, 14, Suppl. 1, 109-122.
142. Schleifer, M., Weiss, G., Cohen, N., Elman, M., Crejic, H., & Kruger, E. (1975). Hyperactivity in preschoolers and the effect of methylphenidate. American Journal of Orthopsychiatry, 45, 33-50.
143. Schmidt, M., Kruesi, M., Elia, J., Borcherding, B., Elin, R., Hosseini, J., McFarlin, K., & Hamburger, S. (1994). Effect of dextroamphetamine and methylphenidate on calcium and magnesium concentrations in hyperactive boys. Psychiatry Research, 54, 199-210.
144. Schmued, L.C., & Bowyer, J.F. (1997). Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants. Brain Research, 759, 135-140.
145. Schneider, S.C., & Tan, G. (1997). Attention-deficit hyperactivity disorder: In pursuit of diagnostic accuracy. Postgraduate Medicine, 101, 231-240.
146. Segal, D.S. (1975). Behavioral and neurochemical correlates of repeated d-amphetamine administration. In A. J. Mandell (Ed.). Neurobiological mechanisms of adaptation and behavior, pp. 247-262. New York: Raven Press.
147. Segal, D.S., Weinberger, S.B., Cahill, J., & McCunney, S.J. (1980). Multiple daily amphetamine administration: Behavioral and neurochemical alterations. Science, 207, 904-907.
148. Shaywitz, S.E., Hunt, R.D., Jatlow, P., Cohen, D.J., Young, J.G., Pierce, R.N., Anderson, G.M., & Shaywitz, B.A. (1985). Psychopharmacology of attention deficit disorder: Pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics, 69, 688-694.
149. Sheng, P., Ladenheim, B., Moran, T.H., Wang X.-B., & Cadet, J.L. (1996). Methamphetamine-induced neurotoxicity is associated with increased striatal AP-1 DNA-binding activity in mice. Molecular Brain Research, 42, 171-174.
150. Sleator, E.K., Ullmann, R.K., & von Neuwman, A. (1982). How do hyperactive children feel about taking stimulants and will they tell the doctor? Clinical Pediatrics, 21, 475-479.
151. Solanto, M.V., & Wender, E.H. (1989). Does methylphenidate constrict cognitive functioning? Journal of the American Academy of Child and Adolescent Psychiatry, 28, 897-902.
152. Sonsalla, P.K., Jochnowitz, N.D., Zeevalk, G.D., Oostveen, J.A., & Hall, E.D. (1996). Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Research, 738, 172-5.
153. Spencer, T.J., Biederman, J., Harding, M., O'Donnell, D., Faraone, S., & Wilens, T.E. (1996). Growth deficits in ADHD children revisited: Evidence for disorder-associated growth delays? Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1460-1469.
154. Spotts, J.V. & Spotts, C.A. (Eds.) (1980). Use and abuse of amphetamine and its substitutes. Rockville, MD: National Institute on Drug Abuse. DHEW Publication No. (ADM) 80-941.
155. Sroufe, L.A., & Stewart, M.A. (1973). Treating problem children with stimulant drugs. New England Journal of Medicine, 289, 407-413.
156. Swanson, J.M. (circa 1993). Research synthesis of the effects of stimulant medication on children with attention deficit disorder: A review of reviews. Executive summaries of research syntheses and promising practices on the education of children with attention deficit disorder. Division of Innovation and Development, Office of Special Education Programs, Office of Special Education and Rehabilitation Services, US Department of Education, Washington, DC.
157. Swanson, J.M. (1993, January 27-29). Medical intervention for children with attention deficit disorder. Proceedings of the Form on the Education of Children with Attention Deficit Disorder, pp. 27-34. Washington, DC: US Department of Education, Office of Special Education and Rehabilitation Services and Office of Special Education Programs, Division of Innovation and Development.
158. Swanson, J.M., Cantwell, D., Lerner, M., McBurnett, K., Pfiffner, L. & Kotkin, R. (1992, fall). Treatment of ADHD: Beyond medication. Beyond Behavior 4, 1, pp. 13-16 and 18-22.
159. Swanson, J.M., & Castellanos, F.X. (1998). Biological bases of attention deficit hyperactivity disorder: Neuroanatomy, genetics, and pathophysiology. NIH consensus development conference program and abstracts: Diagnosis and treatment of attention deficit hyperactivity disorder, pp. 37-42. Rockville, MD: National Institutes of Health.
160. Tannock, R., Schachar, R.J., Carr, R.P., & Logan, G.D. (1989). Dose-response effects of methylphenidate on academic performance and over behavior in hyperactive children. Pediatrics, 84, 648-657.
161. Taylor, E. (1994). Syndromes with attention deficit and hyperactivity. In M. Rutter, Taylor, E., & Hersov, L. (Eds.). Child and adolescent psychiatry: Modern approaches, pp. 285-307. Oxford, England: Blackwell.
162. 3H]methylphenidate binding sites in rat brain. European Journal of Pharmacology, 113, 155-157.
163. Vitiello, B. (1998). Pediatric psychopharmacology and interaction between drugs and the developing brain. Canadian Journal of Psychiatry, 43, 582-584.
164. Volkow, N.D., Wang, G.J., Fowler, J.S., Logan, J., Angrist, B., Hitzemann, R., Lieberman, J., & Pappas, N. (1997). Effects of methylphenidate on regional brain glucose metabolism in humans: Relationship to dopamine D2 receptors. American Journal of Psychiatry, 154, 50-55.
165. Wagner, G.C., Ricaurte, G.A., Johanson, C.E., Schuster, C.R., & Seiden, L.S. (1980). Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate nucleus. Neurology, 30, 547-550.
166. Wallach, M.B. (1974). Drug-induced stereotypical behavior: Similarities and differences. In Usdin, E. (Ed.). Neuropsychopharmacology of monoamines and
167. Wamsley, J.K., Byerley, W.F., McCabe, R.T., McConnell, E.J., Dawson, T.M., & Grosser, B.I. (1987). Receptor alterations associated with serotonergic agents: An autographic analysis. Journal of Clinical Psychiatry, 48(3), (supp), 19-85.
168. Wang, G-J, Volkow, N., Fowler, J., Ferrieri, R., Schlyer, D., Alexoff, D., Pappas, N., Lieberman, J., King, P., Warner, D., Wong, C., Hitzemann, R., & Wolf, A. (1994). Methylphenidate decreases regional cerebral blood flow in normal human subjects. Life Sciences, 54, 143-146.
169. Weiler, I. J., Hawrylak, N., & Greenough, W.T. (1995). Morphogenesis in memory formation: Synaptic and cellular mechanisms. Behavioral Brain Research, 66, 1-6.
170. Weiss, G., Hechtman, L., Milroy, T., & Perlman, T. (1985). Psychiatric status of hyperactive adults. Journal of the American Academy of Child and Adolescent Psychiatry, 24, 211-220.
171. Weiss, F., Imperato, A., Casu, M.A., Mascia, M.S., & Gessa G.L. (1997). Opposite effects of stress on dopamine release in the limbic system of drug-naive and chronically amphetamine-treated rats. European Journal of Pharmacology, 337, 219-222.
172. Whalen, C.K., Henker, B., & Granger D.A. (1989). Ratings of medication effects in hyperactive children: Viable or vulnerable? Behavioral Assessment, 11, 179-199.
173. Whalen, C. & Henker, B. (1997). Stimulant pharmacotherapy for attention-deficit/hyperactivity disorders: An analysis of progress, problems, and prospects. In S. Fisher & R. Greenberg, R. (Eds.) From placebo To panacea: Putting psychotherapeutic drugs to the test, pp. 323-356. New York: J. Wiley & Sons.
174. Wong, D.T. & Bymaster, F.P. (1981, April). Subsensitivity of serotonin receptors after long-term treatment of rats with fiuoxetine, Research Communications in Chemical Pathology and Pharmacology, 32, 41-51.
175. Wong, D.T., Reid, L.R., Bymaster, F.P., & Threlkeld, P.G. (1985). Chronic effects of fluoxetine, a selective inhibitor of sertonin uptake, on neurotransmitter receptors. Journal of Neural Transmission, 64, 251-269.
176. Yuan, J., McCann, U., & Ricaurte, G. (1997). Methylphenidate and brain dopamine neurotoxicity. Brain Research, 767, 172-175.
177. Zaczek, R., Battaglia, G., Contrera, J.F., Culp, S., & De Souza, E.B. (1989). Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine. Toxicology and Applied Pharmacology, 100, 227-233.